GlassScriptPhysician profile
Novelette E Thompson
NPI 1962412296
$5,290.53
in general payments reported to CMS, 2019-2025
40 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2021: $250 · 2022: $220 · 2023: $1,029 · 2024: $2,338 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,986 · Travel and Lodging: $612 · Gift: $59.40 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,985.72 |
| Travel and Lodging | $611.56 |
| Gift | $59.40 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,070.93 | 2021-2025 | Minimed 780g |
| Novo Nordisk INC | $565.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $425.96 | 2019-2025 | Evenity, Prolia, Tepezza |
| Insulet Corporation | $281.13 | 2019-2025 | Omnipod |
| Radius Health, INC. | $241.45 | 2023-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $236.92 | 2023-2025 | |
| Lilly USA, LLC | $215.26 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $190.82 | 2023-2025 | Korlym |
| Mannkind Corporation | $184.00 | 2021-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $181.63 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Beta Bionics, INC. | $166.35 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Dexcom, INC. | $155.06 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.08 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $114.30 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $107.52 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $99.91 | 2023-2025 | Teriparatide |
| Neurocrine Biosciences, INC. | $86.24 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $81.95 | 2023-2024 | |
| Abbott Laboratories | $63.22 | 2022-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $59.28 | 2024 | Cologuard Collection Kit |
| Rhythm Pharmaceuticals, INC. | $59.13 | 2021-2025 | Imcivree |
| Astellas Pharma US INC | $53.98 | 2023-2024 | Veozah |
| Verity Pharmaceuticals INC. | $52.72 | 2024-2025 | Tlando |
| Recordati_rare_diseases_inc. | $52.42 | 2025 | Isturisa |
| Ascendis Pharma Endocrinology INC | $44.93 | 2025 | Yorvipath |
| Cequr Corporation | $37.90 | 2024-2025 | Cequr Simplicity |
| Amryt Pharma Holdings LTD | $37.73 | 2023 | Mycapssa |
| Acella Pharmaceuticals, LLC | $32.76 | 2024-2025 | NP Thyroid 60 |
| Madrigal Pharmaceuticals | $31.45 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $25.54 | 2024 | Strensiq |
| Lifescan, INC. | $24.04 | 2022 | |
| Horizon Therapeutics Plc | $21.53 | 2022 | |
| Sequel Med Tech, LLC | $20.45 | 2025 | Twiist |
| Esperion Therapeutics, INC. | $20.08 | 2024 | Nexletol |
| Glaxosmithkline, LLC. | $19.86 | 2025 | Shingrix |
| Pfizer INC. | $17.37 | 2023 | |
| Antares Pharma, INC. | $17.18 | 2025 | Xyosted |
| Abbvie INC. | $15.99 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $15.72 | 2023 | Crysvita |
| Tolmar, INC. | $13.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Novelette Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.